New drug cocktail aims to shrink Hard-to-Treat colorectal tumors
NCT ID NCT07683949
First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time
Summary
This clinical trial is testing whether combining two drugs—capecitabine (a chemotherapy pill) and lenvatinib (a targeted therapy)—can shrink tumors in people with advanced colorectal cancer that has stopped responding to standard treatments. The study enrolls adults aged 19 and older with metastatic or unresectable colorectal cancer. In the first phase, researchers find the best dose of lenvatinib; in the second phase, they measure how many patients' tumors shrink or disappear.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- capecitabine and lenvatinib
- What this could lead to
- If successful, this combination could offer a new treatment option for people with advanced colorectal cancer who have run out of standard options.
- What could go wrong
- This is an early-phase trial (Phase I/II) with a small number of participants, so the benefits are uncertain. Side effects from the drug combination may be significant.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED COLORECTAL CANCER (PART 1) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
172, Dolma-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, Korea Seoul National University Bundang Hospital, Health Care Innovation Park 5Fr. D5-01
Seongnam-si, Out of US, 13605, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Pronged attack shrink Hard-to-Treat colorectal tumors?
- Can a Two-Drug attack shrink Hard-to-Treat colorectal tumors?
- Can a four-drug cocktail shrink hard-to-treat colorectal cancer?
- Can a Drug-Radiation combo outsmart Treatment-Resistant colorectal cancer?
- Can a cholesterol drug help immunotherapy fight colorectal cancer?
- Adding a Blood-Vessel blocker to maintenance chemo may extend control of advanced colorectal cancer